Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing lipid nanocrystal (LNC) delivery technology and its lead product candidate MAT2203. The company is currently centered on advancing MAT2203 toward late-stage development and seeking a partner or transaction to monetize the asset and fund future work.

2.79

2.79

— Matinas BioPharma Holdings, Inc.
%
MAT220370% Lead lipid nanocrystal product candidate being advanced through clinical development and partnership discussions.
LNC Platform Technology20% Proprietary delivery platform intended to improve formulation, delivery and commercialization potential of drug assets.
R&D Services and Development Support10% Internal and outsourced research, clinical, CMC and regulatory work supporting pipeline advancement.

Matinas does not sell commercial pharmaceutical products today; its economic counterparties are primarily potential...

  • Pharmaceutical partnership candidatesprimary

    Large or well-funded biotech/pharma companies that could license MAT2203 and fund Phase 3 development and commercialization.

  • Strategic licensing counterpartiesprimary

    Companies evaluating the LNC platform or related assets for non-dilutive licensing or acquisition.

  • Clinical research vendorssecondary

    CROs, laboratories and consultants that provide trial design, execution, analysis and regulatory support.

  • Government and third-party funding sourcessecondary

    NIH and other non-dilutive funding providers that may support preclinical or clinical work.

The company is headquartered in the United States and its disclosed operating footprint is centered on U.S...

  • •Headquartered in the United States
  • •R&D and regulatory work are primarily U.S.-based
  • •Clinical studies may involve U.S. CROs and NIH support
  • •No meaningful commercial geography yet disclosed
  • •Future partner commercialization could expand global reach

Matinas is prioritizing a partnership or licensing transaction for MAT2203 to secure non-dilutive capital and...

01
Partner MAT2203short-term

A funded partner can advance the asset faster and reduce Matinas' capital burden.

02
Preserve liquidityshort-term

The company is loss-making and needs to extend runway while it seeks strategic options.

03
Broaden strategic optionalitymedium-term

Additional assets or a merger could create value if MAT2203 monetization is delayed.

Matinas is a pre-revenue biotech with a high dependence on external financing and successful partnering of MAT2203...

critical

Financing shortfall / going concern pressure

The company expects continued losses and needs new capital to fund operations and trials.

Scope
Cash runway, ability to continue as a going concern
Materiality
high
high

MAT2203 development failure or delay

Value creation depends heavily on advancing the lead candidate into Phase 3 and beyond.

Scope
Pipeline concentration
Materiality
high
high

Partnering and licensing execution risk

The strategy relies on finding a capable third-party partner on acceptable terms.

Scope
Monetization of lead asset
Materiality
high
high

Dilution from equity financings

Management may need to issue common stock or convertible securities to raise funds.

Scope
Shareholder ownership and capital structure
Materiality
high
medium

Warrant and preferred stock complexity

Recent financings included warrants and preferred stock that can affect reported earnings and dilution.

Scope
Valuation and share count
Materiality
medium
Warrant liability fair value
Can materially move other income/expense and net loss
Research and development expense timing
Affects operating loss and quarter-to-quarter comparability
Goodwill and intangible impairment
Potential non-cash write-downs
Stock-based compensation
Raises operating expenses without cash outflow

Liminatus Pharma, Inc.

LIMN · Biological Products, (No Diagnostic Substances)

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

Zenas BioPharma, Inc.

ZBIO · Pharmaceutical Preparations

Dianthus Therapeutics, Inc. /DE/

DNTH · Pharmaceutical Preparations

Larimar Therapeutics, Inc.

LRMR · Pharmaceutical Preparations

GT Biopharma, Inc.

GTBP · Pharmaceutical Preparations

: 28/04/2026